Related Experiment Video
Updated: Aug 4, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Mild heart failure: why the switch to ACE inhibitors?
Geriatrics
|November 1, 1993
Summary
Early use of ACE inhibitors is now recommended for patients with asymptomatic or mildly symptomatic LV dysfunction. This approach reduces heart failure, death, and recurrent heart attacks, with careful monitoring to avoid side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Traditional congestive heart failure management relied on diuretics, rest, and digitalis.
- Limited evidence existed for proactive intervention in early-stage cardiac dysfunction.
Purpose of the Study:
- To evaluate the efficacy of early Angiotensin-Converting Enzyme (ACE) inhibitor therapy in patients with left ventricular (LV) dysfunction.
- To determine the impact of ACE inhibitors on heart failure progression, mortality, and myocardial infarction (MI) recurrence.
Main Methods:
- Review of recent clinical evidence and guidelines.
- Analysis of patient outcomes in studies involving ACE inhibitor administration for LV dysfunction and post-MI patients.
Main Results:
- ACE inhibitors significantly reduce the incidence of symptomatic heart failure in asymptomatic patients with reduced ejection fraction.
- Early ACE inhibitor therapy in post-MI patients decreases mortality risk, lowers the probability of developing heart failure, and reduces MI recurrence.
- Careful titration and dose adjustment of diuretics can mitigate risks like hypotension and azotemia.
Conclusions:
- Early and aggressive ACE inhibitor therapy is now a cornerstone in managing patients with LV dysfunction, including those with asymptomatic or mild symptoms.
- ACE inhibitors offer substantial benefits in reducing morbidity and mortality associated with heart failure and post-MI recovery.
- Optimal patient outcomes with ACE inhibitors can be achieved through individualized dosage titration and monitoring for potential adverse effects.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...